Market Overview

Market Research Future (MRFR) has published a report about the global influenza diagnostics market size expects 5.3% CAGR during the forecast period between 2023-2032. In terms of cash, this market is expected to grow with USD 1.81 billion by 2032.

Moreover, the increasing prevalence of influenza strains worldwide is propelling the adoption of rapid diagnostic solutions in both clinical and point-of-care settings. Healthcare facilities are leveraging the benefits of RIDTs and IRATs to expedite the diagnostic workflow and minimize the risk of influenza transmission within healthcare settings. These tests play a pivotal role in surveillance activities, aiding healthcare authorities in monitoring influenza trends and implementing targeted intervention strategies. Furthermore, the continuous advancements in technology are enhancing the performance characteristics of these tests, such as sensitivity and specificity, thereby boosting their acceptance among healthcare providers. As a result, the influenza rapid antigen test is poised for substantial growth, driven by the rising demand for rapid and accurate diagnostic solutions that can effectively address the evolving challenges posed by influenza outbreaks.Top of Form

The Influenza Diagnostics Market is witnessing steady growth driven by the increasing prevalence of influenza worldwide. This market encompasses a wide range of diagnostic tests including rapid influenza diagnostic tests (RIDTs), molecular tests, and serological assays. Key factors influencing market growth include the development of advanced diagnostic technologies, rising awareness about early diagnosis, and government initiatives promoting influenza control. Additionally, the COVID-19 pandemic has highlighted the importance of efficient diagnostic tools, further propelling market expansion. However, challenges such as the emergence of new influenza strains and stringent regulatory requirements may hinder market growth. Overall, the market shows promising prospects with continuous advancements in diagnostic techniques.

Market Segmentation

The global influenza diagnostics market is segmented on the basis of types, tests, and region. The segmentation of types comprises of type A flu, type B flu, type C flu. The three forms of type A are bird flu, seasonal flu, and Swine flu. Bird Flu is known as Avian Influenza which is caused by viruses adapted to birds. It can be caused by eating infected birds. Seasonal flu is common cold whose viruses become active only during the change of seasons as human body becomes adapt to the new season slowly. Similar to bird flu, swine flu is an infection caused by any one of several types of swine influenza viruses. Swine influenza virus (SIV) or swine-origin influenza virus (S-OIV) are the viruses causing this infection. These viruses are found in pigs. Type B flu is found only in humans. Influenza type B viruses are not classified by subtype and do not cause pandemics. It is caused by a genus called Influenzavirus B which is from the virus family Orthomyxoviridae. Type C Influenza viruses are from Orthomyxoviridae family. They are not as severe as Type A or B but can cause local epidemics.

On the basis of tests, the market has been segmented into direct fluorescent antibody (DFA) tests, molecular tests, nucleic acid sequence-based amplification (NASBA) tests, rapid influenza detection tests (RIDT), serological assays, simple amplification-based assays (SAMBA) and loop-mediated isothermal amplification-based assays (LAMP). RITD is the most common test for influenza, as it can confirm influenza in just 30 minutes.

Serological assays are segmented into primary serological tests, secondary serological tests, and tertiary serological tests. Primary serological tests cover enzyme-linked immunosorbent assay (ELISA), immunofluorescent antibody technique (IFAT) and radioimmunoassay (RIA). Secondary Serological tests include agglutination tests, complement fixation tests (CFT), precipitation tests, serum neutralization tests (SNT) and toxin-antitoxin test.

Key Players

Global influenza diagnostics market players include Alere (USA), BD (USA), Becton Dickinson (USA), BioMérieux SA (France), Cepheid (USA), Hardy Diagnostics(USA), LifeSign LLC.(USA), Meridian Bioscience, Inc.(USA), Quidel Corporation (USA), Roche Molecular Systems Inc.(Switzerland), and Sekisui Diagnostics (USA).

Regional Analysis

The regional segmentation of the global influenza diagnostics market insight is into the Americas (North America & South America), Europe, Asia Pacific, and Middle East & Africa (MEA). North America is believed to be the largest market for global influenza diagnostics due to advanced healthcare facilities and the increasing presence of major market players in this region. Compared to North America, South America is a moderately smaller market, but that is not due to lack of demand but due to the lack of awareness, lack of advanced technology and lesser budgets for healthcare. In North America, the largest markets are Canada and the United States of America (USA).

After North America, Europe is the largest market for influenza diagnostics. Here due to reasons same as North America, Western Europe stands with the lion's share in Europe market, compared to Eastern Europe. In Western Europe, the biggest markets are France, Germany, Italy, Spain and the United Kingdom (UK), followed by the rest of Europe.

During the forecast period, Asia Pacific region is expected to experience large-scale growth of influenza diagnostics market with China, India, Japan and South Korea emerging as major markets. Remarkable growth is also expected in remaining countries of Asia Pacific region.

 However, compared to the Asia Pacific, MEA is expected to have limited growth, with Egypt, Saudi Arabia and the United Arab Emirates (UAE) emerging as the best bets for influenza diagnostics market investors. The low market in the MEA region is primarily due to the lack of technology and education.

For more information, Please Visit us @ Market Research Future